Jeil Pharma Holdings Inc

Symbol: 002620.KS

KSC

11280

KRW

Market price today

  • -21.7409

    P/E Ratio

  • 0.0000

    PEG Ratio

  • 173.16B

    MRK Cap

  • 0.00%

    DIV Yield

Jeil Pharma Holdings Inc (002620-KS) Stock Price & Analysis

Shares Outstanding

0M

Gross Profit Margin

0.26%

Operating Profit Margin

0.02%

Net Profit Margin

-0.01%

Return on Assets

-0.01%

Return on Equity

-0.02%

Return on Capital Employed

0.04%

Company general description and statistics

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
CEO:Mr. Seung-Soo Han
Full-time employees:39
City:Seoul
Address:343, Sapyeong-daero
IPO:2000-01-04
CIK:

Jeil Pharma Holdings Inc manufactures and sells ingredients of drugs, incrementally modified drugs, and generic drugs in South Korea. The company offers active pharmaceutical ingredients in the areas of antibiotics, gastrointestinal, cardiovascular, neuropsychiatry, oncology, endocrinology, urology, antiviral, and antihistamines, as well as patch products. It also provides finished dosage forms in the areas of anti-bacteria and anti-fungal, anti-virus, cardiovascular, endocrinology, neurology, gastrointestinal, urology, oncology, anti-histamine, rheumatology, respiratory, otolaryngological, heaptic, laxatives, and purgatives. The company exports its products to approximately 40 countries in the Association of Southeast Asian Nations, Central and South America, Africa, etc. Jeil Pharma Holdings Inc was founded in 1959 and is headquartered in Seoul, South Korea.

General Outlook

When we look at how much money they make before expenses, they keep 0.264% as profit. This shows they're good at controlling costs and are financially stable. Their operating profit, which is money made from regular business activities, is 0.023%. This means they run their business efficiently. Lastly, after paying all their bills, they still have a profit of -0.010%. This tells us they're good at keeping money after all costs.

Return on Investments

The company's asset efficiency, represented by a robust -0.009% return, is a testament to Jeil Pharma Holdings Inc's adeptness in optimizing resource deployment. Jeil Pharma Holdings Inc's utilization of its assets to generate profits is strikingly evident through a noteworthy return on equity of -0.023%. Furthermore, the proficiency of Jeil Pharma Holdings Inc in capital utilization is underscored by a remarkable 0.039% return on capital employed.

Stock Prices

Jeil Pharma Holdings Inc's stock prices have been subject to undulating patterns. The peak stock value during this interval surged to $11080, while its low point bottomed out at $10840. This variance in figures offers investors a lucid insight into the roller-coaster ride that is Jeil Pharma Holdings Inc's stock market.

Liquidity Ratios

Analyzing 002620.KS liquidity ratios reveals its financial health of the firm. The current ratio of 93.19% gauges short-term asset coverage for liabilities. The quick ratio (62.48%) assesses immediate liquidity, while the cash ratio (8.98%) indicates cash reserves.

cards.indicatorcards.value
Current Ratio93.19%
Quick Ratio62.48%
Cash Ratio8.98%

Profitability Ratios

002620.KS profitability indicators offer a lens into its earnings landscape. A pretax profit margin of -2.06% underscores its earnings before tax deductions. The effective tax rate stands at 4.50%, revealing its tax efficiency. The net income per EBT, 48.43%, and the EBT per EBIT, -89.40%, provide insights into its earnings hierarchy. Lastly, with an EBIT per revenue ratio of 2.30%, we grasp its operational profitability.

cards.indicatorcards.value
Pretax Profit Margin-2.06%
Effective Tax Rate4.50%
Net Income per EBT48.43%
EBT per EBIT-89.40%
EBIT per Revenue2.30%

Operational Efficiency

Operational metrics shed light on its business agility. With an operating cycle of 0.93, it details the span from stock purchase to revenue. The 1 days it takes to settle debts showcases its creditor relations.

cards.indicatorcards.value
Days of Sales Outstanding62
Days of Inventory Outstanding77
Operating Cycle167.97
Days of Payables Outstanding95
Cash Conversion Cycle73
Receivables Turnover4.03
Payables Turnover3.83
Inventory Turnover4.71
Fixed Asset Turnover3.50
Asset Turnover0.91

Cash Flow Ratios

Peering into the cash flow metrics reveals liquidity and operational efficiency. The operating cash flow per share, -287.64, and free cash flow per share, -933.17, depict cash generation on a per-share basis. The cash per share value, 3851.90, showcases liquidity position. A payout ratio of -0.05 highlights the portion of earnings distributed as dividends. Lastly, the operating cash flow sales ratio, -0.01, offers insight into cash flow relative to sales.

cards.indicatorcards.value
Operating Cash Flow per Share-287.64
Free Cash Flow per Share-933.17
Cash per Share3851.90
Payout Ratio-0.05
Operating Cash Flow Sales Ratio-0.01
Free Cash Flow to Operating Cash Flow Ratio3.24
Cash Flow Coverage Ratio-0.03
Short Term Coverage Ratio-0.03
Capital Expenditure Coverage Ratio-0.45
Dividend Paid and Capex Coverage Ratio-0.43
Dividend Payout Ratio0.01

Debt and Leverage Ratios

Diving into debt and leverage metrics unveils the company's financial structure. The debt ratio, at 19.53%, highlights its total liabilities relative to assets. With a debt-equity ratio of 0.54, we discern the balance between debt and equity financing. The long-term debt to capitalization, 3.18%, and total debt to capitalization, 34.98%, ratios shed light on its capital structure. An interest coverage of 1.73 indicates its ability to manage interest expenses.

cards.indicatorcards.value
Debt Ratio19.53%
Debt Equity Ratio0.54
Long Term Debt to Capitalization3.18%
Total Debt to Capitalization34.98%
Interest Coverage1.73
Cash Flow to Debt Ratio-0.03
Company Equity Multiplier2.75

Per Share Data

Speaking about the per share data offers a perceptive view of financial distribution. The revenue per share, 51769.08, provides a glimpse into top-line earnings distributed across each share. Net income per share, -1058.54, reflects the portion of profit attributed to each share. The book value per share, 20810.28, represents the net asset value distributed per share, while the tangible book value per share, 22423.80, excludes intangible assets.

cards.indicatorcards.value
Revenue Per Share51769.08
Net Income Per Share-1058.54
Book Value Per Share20810.28
Tangible Book Value Per Share22423.80
Shareholders Equity Per Share20810.28
Interest Debt Per Share11888.68
Capex Per Share-640.78

Growth Ratios

Delving into growth metrics provides a snapshot of financial expansion. The revenue growth rate, 1.40%, indicates top-line expansion, while the gross profit growth, 345.49%, reveals profitability trends. EBIT growth, 375.84%, and operating income growth, 375.84%, offer insights into operational profitability progression. The net income growth, 85.41%, showcases bottom-line expansion, and the EPS growth, 85.98%, measures the growth in earnings per share.

cards.indicatorcards.value
Revenue Growth1.40%
Gross Profit Growth345.49%
EBIT Growth375.84%
Operating Income Growth375.84%
Net Income Growth85.41%
EPS Growth85.98%
EPS Diluted Growth85.98%
Weighted Average Shares Growth-100.00%
Weighted Average Shares Diluted Growth-100.00%
Dividends per Share Growth-100.00%
Operating Cash Flow Growth100.00%
Free Cash Flow Growth100.00%
10-Year Revenue Growth per Share-100.00%
5-Year Revenue Growth per Share-100.00%
3-Year Revenue Growth per Share-100.00%
10-Year Operating CF Growth per Share-100.00%
5-Year Operating CF Growth per Share100.00%
3-Year Operating CF Growth per Share100.00%
10-Year Net Income Growth per Share-100.00%
5-Year Net Income Growth per Share-100.00%
3-Year Net Income Growth per Share-100.00%
10-Year Shareholders Equity Growth per Share-100.00%
5-Year Shareholders Equity Growth per Share-100.00%
3-Year Shareholders Equity Growth per Share-100.00%
10-Year Dividend per Share Growth per Share-100.00%
5-Year Dividend per Share Growth per Share-100.00%
3-Year Dividend per Share Growth per Share-100.00%
Receivables Growth-100.00%
Inventory Growth-100.00%
Asset Growth1.67%
Book Value per Share Growth-100.00%
Debt Growth-100.00%
R&D Expense Growth-100.00%
SGA Expenses Growth-100.00%

Other Metrics

Venturing into other key metrics unveils diverse facets of financial performance. The enterprise value, 319,130,834,709, captures the company's total value, considering both debt and equity. Income quality, 0.27, assesses the reliability of reported earnings. The sales, general, and administrative to revenue ratio, 0.05, gauges operational efficiency, while the research and development to revenue, 5.59%, highlights investment in innovation. The ratio of intangibles to total assets, 6.59%, indicates the value of non-physical assets, and capex to operating cash flow, 222.77%, measures reinvestment capability.

cards.indicatorcards.value
Enterprise Value319,130,834,709
Income Quality0.27
Sales General and Administrative to Revenue0.05
Research and Development to Revenue5.59%
Intangibles to Total Assets6.59%
Capex to Operating Cash Flow222.77%
Capex to Revenue-1.24%
Capex to Depreciation-78.34%
Stock-Based Compensation to Revenue0.07%
Graham Number22262.98
Return on Tangible Assets-1.98%
Graham Net Net-13485.56
Working Capital-28,108,622,137
Tangible Asset Value344,230,569,382
Net Current Asset Value-93,283,715,679
Invested Capital1
Average Receivables189,999,835,000
Average Payables158,508,724,500
Average Inventory119,272,910,674.5
Days Sales Outstanding91
Days Payables Outstanding95
Days of Inventory On Hand77
ROIC2.28%
ROE-0.05%

Valuation Ratios

Exploring the valuation ratios offers insights into perceived market value. The price to book value ratio, 0.54, and the price to book ratio, 0.54, reflect the market's valuation relative to the company's book value. The price to sales ratio, 0.22, provides a perspective on valuation in relation to sales. Ratios like price to free cash flows, -12.11, and price to operating cash flows, -39.28, gauge market valuation against cash flow metrics.

cards.indicatorcards.value
Price Book Value Ratio0.54
Price to Book Ratio0.54
Price to Sales Ratio0.22
Price Cash Flow Ratio-39.28
Enterprise Value Multiple1.08
Price Fair Value0.54
Price to Operating Cash Flow Ratio-39.28
Price to Free Cash Flows Ratio-12.11
Price to Tangible Book Ratio0.57
Enterprise Value to Sales0.40
Enterprise Value Over EBITDA13.22
EV to Operating Cash Flow-72.27
Earnings Yield-8.87%
Free Cash Flow Yield-7.78%
security
Trusted project
“All information displayed on the site is verified. High quality project and financial performance”
Eugene Alexeev
NumFin Founder and investing enthusiast

Frequently Asked Question

How many company shares are outstanding in 2024?

There are stock number shares outstanding of Jeil Pharma Holdings Inc (002620.KS) on the KSC in 2024.

What is P/E ratio of enterprise in 2024?

The current P/E ratio of enterprise is -21.741 in 2024.

What is the ticker symbol of Jeil Pharma Holdings Inc stock?

The ticker symbol of Jeil Pharma Holdings Inc stock is 002620.KS.

What is company IPO date?

IPO date of Jeil Pharma Holdings Inc is 2000-01-04.

What is company current share price?

Current share price is 11280.000 KRW.

What is stock market cap today?

The market cap of stock today is 173161197600.000.

What is PEG ratio in 2024?

The current 0.000 is 0.000 in 2024.

What is the number of employees in 2024?

In 2024 the company has 39.